GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045637110 | Oral cavity | EOLP | regulation of myeloid cell differentiation | 51/2218 | 210/18723 | 3.63e-07 | 1.05e-05 | 51 |
GO:001605523 | Oral cavity | EOLP | Wnt signaling pathway | 89/2218 | 444/18723 | 3.66e-07 | 1.06e-05 | 89 |
GO:005108524 | Oral cavity | EOLP | chaperone cofactor-dependent protein refolding | 16/2218 | 34/18723 | 3.85e-07 | 1.10e-05 | 16 |
GO:009031622 | Oral cavity | EOLP | positive regulation of intracellular protein transport | 42/2218 | 160/18723 | 4.18e-07 | 1.19e-05 | 42 |
GO:000095623 | Oral cavity | EOLP | nuclear-transcribed mRNA catabolic process | 33/2218 | 112/18723 | 4.21e-07 | 1.19e-05 | 33 |
GO:003010023 | Oral cavity | EOLP | regulation of endocytosis | 51/2218 | 211/18723 | 4.24e-07 | 1.19e-05 | 51 |
GO:006101423 | Oral cavity | EOLP | positive regulation of mRNA catabolic process | 28/2218 | 87/18723 | 4.26e-07 | 1.19e-05 | 28 |
GO:019873823 | Oral cavity | EOLP | cell-cell signaling by wnt | 89/2218 | 446/18723 | 4.49e-07 | 1.25e-05 | 89 |
GO:000189023 | Oral cavity | EOLP | placenta development | 39/2218 | 144/18723 | 4.49e-07 | 1.25e-05 | 39 |
GO:000660621 | Oral cavity | EOLP | protein import into nucleus | 41/2218 | 155/18723 | 4.58e-07 | 1.27e-05 | 41 |
GO:003461224 | Oral cavity | EOLP | response to tumor necrosis factor | 58/2218 | 253/18723 | 4.79e-07 | 1.32e-05 | 58 |
GO:000926622 | Oral cavity | EOLP | response to temperature stimulus | 45/2218 | 178/18723 | 5.23e-07 | 1.40e-05 | 45 |
GO:001943923 | Oral cavity | EOLP | aromatic compound catabolic process | 92/2218 | 467/18723 | 5.23e-07 | 1.40e-05 | 92 |
GO:00466314 | Oral cavity | EOLP | alpha-beta T cell activation | 41/2218 | 156/18723 | 5.51e-07 | 1.47e-05 | 41 |
GO:005105222 | Oral cavity | EOLP | regulation of DNA metabolic process | 75/2218 | 359/18723 | 5.81e-07 | 1.53e-05 | 75 |
GO:007190023 | Oral cavity | EOLP | regulation of protein serine/threonine kinase activity | 75/2218 | 359/18723 | 5.81e-07 | 1.53e-05 | 75 |
GO:003134621 | Oral cavity | EOLP | positive regulation of cell projection organization | 74/2218 | 353/18723 | 6.00e-07 | 1.56e-05 | 74 |
GO:190210514 | Oral cavity | EOLP | regulation of leukocyte differentiation | 62/2218 | 279/18723 | 6.18e-07 | 1.60e-05 | 62 |
GO:000645824 | Oral cavity | EOLP | 'de novo' protein folding | 18/2218 | 43/18723 | 6.38e-07 | 1.65e-05 | 18 |
GO:005108424 | Oral cavity | EOLP | 'de novo' posttranslational protein folding | 17/2218 | 39/18723 | 6.52e-07 | 1.68e-05 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TG | SNV | Missense_Mutation | rs201480815 | c.3416N>T | p.Ser1139Leu | p.S1139L | P01266 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TG | SNV | Missense_Mutation | | c.4662G>T | p.Trp1554Cys | p.W1554C | P01266 | protein_coding | deleterious(0.01) | benign(0.123) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
TG | SNV | Missense_Mutation | | c.4882N>T | p.Asp1628Tyr | p.D1628Y | P01266 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | | c.3133N>A | p.Gly1045Arg | p.G1045R | P01266 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | | c.5223N>C | p.Gln1741His | p.Q1741H | P01266 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | rs773795717 | c.4645C>T | p.Arg1549Trp | p.R1549W | P01266 | protein_coding | deleterious(0.05) | benign(0.232) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
TG | SNV | Missense_Mutation | novel | c.1093N>A | p.Ala365Thr | p.A365T | P01266 | protein_coding | tolerated(0.44) | benign(0) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | rs146594373 | c.4268N>A | p.Arg1423His | p.R1423H | P01266 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
TG | SNV | Missense_Mutation | | c.746G>A | p.Gly249Asp | p.G249D | P01266 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
TG | SNV | Missense_Mutation | | c.3746N>T | p.Cys1249Phe | p.C1249F | P01266 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIDS | | 12182039 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | FDG | FLUDEOXYGLUCOSE-F18 | 10452315 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | BISPECIFIC ANTIBODY | | 10433080 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PHENYTOIN | PHENYTOIN | 3935423 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISONE | PREDNISONE | 2745931 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | ALL-TRANS-RETINOIC ACID | | 10946899 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | TGFBETA1 | | 10770487,10194419 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIC ACID | | 11563543 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISOLONE | PREDNISOLONE | 3427792,8636270 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | AMIODARONE | AMIODARONE | 8778159 |